Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18)
Document Type
- Journal article (17)
- Preprint (1)
Language
- English (18)
Keywords
- CXCR4 (5)
- PRRT (5)
- multiple myeloma (5)
- PET (4)
- PET/CT (3)
- medicine (3)
- molecular imaging (3)
- neuroendocrine tumor (3)
- positron emission tomography (3)
- theranostics (3)
- FDG (2)
- MAG3 (2)
- NET (2)
- Positronen-Emissions-Tomografie (2)
- RADS (2)
- SSTR (2)
- SSTR-RADS (2)
- bone disease (2)
- chemokine receptor (2)
- peptide receptor radionuclide therapy (2)
- 177Lu (1)
- 18FDG-PET/CT (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATOC (1)
- Arginine (1)
- CXCR4/SDF-1 (1)
- DOTATOC (1)
- FDG PET/CT (1)
- FDG-PET/CT (1)
- Hyperkalaemia (1)
- Lysine (1)
- MI-RADS (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- Multiple myeloma (1)
- PROMISE (1)
- PSMA (1)
- PSMA-RADS (1)
- Positron emission tomography (1)
- SPECT (1)
- Somatostatin receptor expression (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{68}\)Ga-Pentixafor (1)
- amino acids (1)
- autologous transplantation (1)
- cancer (1)
- cardiac neurohormonal system (1)
- cells (1)
- chemokine receptor-4 (1)
- endocrinology (1)
- esophagogastric junction (1)
- experience (1)
- glioblastoma (1)
- glioblastoma multiforme (1)
- glioma (1)
- heart failure (1)
- hyperkalemia (1)
- imaging (1)
- imaging techniques (1)
- immunostaining (1)
- in vivo imaging (1)
- involvement (1)
- kidney function (1)
- macrophages (1)
- magnetic resonance imaging (1)
- malignancies (1)
- management (1)
- microenvironment (1)
- microglial cells (1)
- molecular medicine (1)
- neuroendocrine neoplasia (1)
- nuclear cardiology (1)
- pleural mesothelioma (1)
- positron emission tomography/computed tomography (1)
- prostate cancer (1)
- prostate-specific membrane antigen (1)
- radionuclide therapy (1)
- radiotracer (1)
- renal scintigraphy (1)
- reporting and data system (1)
- somatostatin (1)
- somatostatin receptor (1)
- standardized reporting (1)
- stem-cell transplantation (1)
- survival (1)
- treatment response (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (17)
- Medizinische Klinik und Poliklinik II (7)
- Pathologisches Institut (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Medizinische Klinik und Poliklinik I (2)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Medizinische Strahlenkunde und Zellforschung (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (2)
\(^{11}\)C-methionine-PET in multiple myeloma: a combined study from two different institutions
(2017)
\(^{11}\)C-methionine (MET) has recently emerged as an accurate marker of tumor burden and disease activity in patients with multiple myeloma (MM). This dual-center study aimed at further corroboration of the superiority of MET as positron emission tomography (PET) tracer for staging and re-staging MM, as compared to \(^{18}\)F-2`-deoxy-2`-fluoro-D-glucose (FDG).
78 patients with a history of solitary plasmacytoma (n=4), smoldering MM (SMM, n=5), and symptomatic MM (n=69) underwent both MET- and FDG-PET/computed tomography (CT) at the University Centers of Würzburg, Germany and Navarra, Spain. Scans were compared on a patient and on a lesion basis. Inter-reader agreement was also evaluated. In 2 patients, tumor biopsies for verification of discordant imaging results were available.
MET-PET detected focal lesions (FL) in 59/78 subjects (75.6%), whereas FDG-PET/CT showed lesions in only 47 patients (60.3%; p<0.01), accordingly disease activity would have been missed in 12 patients. Directed biopsies of discordant results confirmed MET-PET/CT results in both cases.
MET depicted more FL in 44 patients (56.4%; p<0.01), whereas in two patients (2/78), FDG proved superior. In the remainder (41.0%, 32/78), both tracers yielded comparable results. Inter-reader agreement for MET was higher than for FDG (κ = 0.82 vs κ = 0.72).
This study demonstrates higher sensitivity of MET in comparison to standard FDG to detect intra- and extramedullary MM including histologic evidence of FDG-negative, viable disease exclusively detectable by MET-PET/CT. MET holds the potential to replace FDG as functional imaging standard for staging and re-staging of MM.